Baird analyst Jack Allen lowered the firm’s price target on Instil Bio to $5 from $14 and keeps an Outperform rating on the shares. The analyst said he remains enthusiastic about the potential for ITIL-306 and TIL therapies in the long term and hence maintains his rating, he expects this will remain a "show me" story until Instil is able to produce ITIL-306 data which is expected in 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TIL:
- Instil Bio discontinues ITIL-168 clinical programs
- Instil Bio prioritizes CoStAR-TIL program, reduces headcount by 60%
- Instil Bio treatment of stage IB2 to IV cervical cancer granted orphan status
- Instil Bio reports Q3 EPS (43c), consensus (44c)
- Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
